Use of Tinzaparin for Anticoagulation in Hemodialysis (HEMO-TIN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age >= 18 years
End stage renal disease maintained on outpatient hemodialysis for >= 3 months
Frequency of hemodialysis: 3 times per week
Anticoagulation with an unfractionated heparin protocol for at least 4 weeks
Patient or legal guardian able to provide written consent
Baseline INR <= 1.3
Baseline platelet count >= 80,000 x 10^9/L
Therapeutic systemic anticoagulation
Clinically apparent bleeding in the last 2 months
High risk of bleeding
Planned major surgery in the next 4 months
Major surgery in the past 48 hours
Pregnant or lactating
Child bearing potential
Allergy/intolerance to heparin or history of heparin induced thrombocytopenia
Current participation in a related randomized drug trial